Comprehensive Analysis of the Neurodegenerative Disorder Therapeutics Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the neurodegenerative disorder therapeutics market grown over the years?
In recent times, there has been significant growth in the market size for therapeutics related to neurodegenerative disorders. The projected growth is from $18.53 billion in 2024 to $20.04 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.1%. Various factors such as an aging population, increased occurrence of neurodegenerative disorders, amplified life expectancy, enhanced investments by pharmaceutical companies, awareness, and advocacy have contributed to this growth seen in the historical period.
What Is the forecasted market size and growth rate for the neurodegenerative disorder therapeutics market?
Anticipated expansion is strong for the neurodegenerative disorder therapeutics market, which is projected to surge to $28.33 billion by 2029, with a compound annual growth rate (CAGR) of 9.0%. The growth within this prediction horizon is due to the increasing demand for personalized medicine, targeted therapy, an uplift in the availability of clinical trials, and upsurging healthcare spending. Some of the key trends for the forecast period would be disease-modifying treatments, non-drug interventions, telemedicine and remote patient monitoring, advancements in technology, precision therapeutics, digital health approaches, and biomarker-dependent trials.
Get your neurodegenerative disorder therapeutics market report here!
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp
What are the major factors driving growth in the neurodegenerative disorder therapeutics market?
The rising incidence of neurodegenerative diseases worldwide is positively contributing to the growth of the neurodegenerative disorder therapeutics market. The surge in the elderly population is linked to the heightened occurrence of these disorders. For example, by 2024, World Population Prospects forecasts that individuals over 60 will reach 2.1 billion by 2050 and those over 80 are expected to triple to 425 million by 2050. The Alzheimer’s Association states that approximately 5.8 million Americans currently suffer from Alzheimer’s disease, and that figure is anticipated to increase to about 14 million by 2050. The rising cases of neurodegenerative diseases in the elderly demographic boosts the demand for therapeutics for these disorders, which in turn is propelling the growth of the neurodegenerative disorder therapeutics market.
What key areas define the segmentation of the global neurodegenerative disorder therapeutics Market?
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp
What are the top market players propelling the growth of the neurodegenerative disorder therapeutics industry?
Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
What are the key trends shaping the future of the neurodegenerative disorder therapeutics market?
Companies manufacturing therapeutics for neurodegenerative ailments are actively engaging in strategic alliances with governmental and non-governmental bodies to expand the discovery and development of treatments for multiple neurodegenerative conditions. Market players in the neurodegenerative disorder therapeutics sector are amplifying their collaborations in an effort to enhance their research and development capacities. This is done with the intention to create novel and more potent therapeutic solutions for neurodegenerative disorders. To illustrate, in July 2022, UK’s NRG Therapeutics, a firm committed to devising therapeutic strategies, teamed up with another UK firm, Domainex, a leading player in drug discovery services, with the aim to construct treatments for neurodegenerative diseases. The collaboration intends to concoct new disease-modifying medicines in the form of small molecules, targeting debilitating chronic neurodegenerative diseases like Parkinson’s disease and motor neuron disease (MND).
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818
What regions are dominating the neurodegenerative disorder therapeutics market growth?
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Browse Through More Similar Reports By The Business Research Company:
Neurosurgery Devices And Equipment Global Market Report 2024
Neurology Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Brain And Neuroimaging Devices Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
